Immunosurveillance by antiangiogenesis: Tumor growth arrest by T cell-derived thrombospondin-1

Cancer Research

Volumn 74, Issue 8, 2014, Pages 2171-2181

  Schadler, Keri L ^a   Crosby, Erika J ^b   Zhou, Alice Yao ^a   Bhang, Dong Ha ^a   Braunstein, Lior ^c   Baek, Kwan Hyuck ^a,d   Crawford, Danielle ^a   Crawford, Alison ^b   Angelosanto, Jill ^b   Wherry, E John ^b   Ryeom, Sandra ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOSPONDIN 1;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNOSURVEILLANCE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIRUS INFECTION;

ANIMALS; CARCINOGENESIS; CELL CULTURE TECHNIQUES; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES; THROMBOSPONDIN 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899572151     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0094     Document Type: Article

References (35)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
3. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8.
4. Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali R, Morgan R, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clinl Invest 2010;120:3953-68.
5. Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan R, Restifo N, et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012;18:1672-83.
6. Matejuk A, Leng Q, Chou ST, Mixson A. Vaccines targeting the neovasculature of tumors. Vasc Cell 2011;3:7.
7. Yan J, Jia R, Song H, Liu Y, Zhang L, Zhang W, et al. A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy. Immunol Lett 2009;126:60-6.
8. Ruan Z, Yang Z, Wang Y, Wang H, Chen Y, Shang X, et al.DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. J Immunother 2009;32:486-91.
9. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 2011;475: 226-30.
10. Bansal R, Tomar T, Ostman A, Poelstra K, Prakash J. Selective targeting of interferon gamma to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth. Mol Cancer Ther 2012;11: 2419-28.
11. Beatty GL, Paterson Y. IFN-g can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol 2000;165:5502-8.
12. Briesemeister D, Sommermeyer D, Loddenkemper C, Loew R, Uckert W, Blankenstein T, et al. Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int J Cancer 2010;128:371-8.
13. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, et al. CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010;18:485-98.
14. Qin Z, Schwartzkopff J, Pradera F, Kammertans T, Seliger B, Pircher H, et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63:4095-100.
15. Hunter CA, Yu D, GeeM, Ngo C, Sevignani C, Goldschmidt M, et al. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol 2001;166: 5878-81.
16. Rankin EB, Yu D, Jiang J, Shen H, Pierce E, Goldschmidt M, et al. An essential role of Th1 responses and interferon-gamma in infectionmediated suppression of neoplastic growth. Cancer Biol Ther 2003; 2:685-91.
17. Harford JB. Viral infections and human cancers: the legacy of Denis Burkitt. Br J Haematol 2012;156:709-18.
18. Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2012;2:a006627.
19. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002;6:1-12.
20. Grossfeld GD, Ginsberg DA, Stein JP, Bochner B, Esrig D, Nichols P, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997;89:219-27.
21. Li Q, Ahuja N, Burger PC, Issa JP. Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene 1999;18: 3284-9.
22. Lawler J, Sunday M, Thibert V, Duquette M, George E, Rayburn H, et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 1998;101: 982-92.
23. Doering T, Crawford A, Angelosanto J, Paley M, Ziegler C, Wherry EJ. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 2012;37: 1130-44.
24. Carbone A, De Paoli P. Cancers related to viral agents that have a direct role in carcinogenesis: pathological and diagnostic techniques. J Clin Pathol 2012;65:680-6.
25. Losikoff PT, Self AA, Gregory SH. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence 2012;3:610-20.
26. Liu Z, Christensson M, Forslaw A, De Meester I, Sundqvist KG. A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals. J Immunol 2009;183:3616-24.
27. Kaur S, Kuznetsova SA, Pendrak ML, Sipes J, Romeo M, Li Z , et al. Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem 2011;286:14991-5002.
28. Van VQ, Baba N, Rubio M, Wakahara K, Panzini B, Richard C, et al. CD47Low status on CD4 effectors is necessary for the contraction/ resolution of the immune response in humans and mice. PLoS ONE 2012;7:e41972.
29. Krispin A, Bledi Y, Atallah M, Trahtemberg U, Verbovetski I, Nahari E, et al. Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states. Blood 2006; 108:3580-9.
30. Venkatraman L, Chia S-M, Narmada Balakrishnan C, White J, Bhowmick S, Forbes D, et al. Plasmin triggers a switch-like decrease in thrombospondin- dependent activation of TGFbeta1. Biophys J 2012; 103:1060-8.
31. Dang E, Barbi J, Yang H, Jinasena D, Yu H, Zheng Y, et al. Control of Th17/Treg balance by hypoxia-inducible factor 1. Cell 2011;146: 772-84.
32. Murdoch C, Muthana M, Lewis CE. Hypoxia regulates macrophage functions in inflammation. J Immunol 2005;175:6257-63.
33. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011;1:83-95.
34. Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie JY, Huang Z, et al. A phase 1 trial of abt-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol 2010;67:313-9.
35. Sahora AI, Rusk AW, Henkin J, McKeegan EM, Shi Y, Khanna C. Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma. J Vet Intern Med 2012;26:1169-76.